Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.

Détails

ID Serval
serval:BIB_459F4CA67A22
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.
Périodique
European Journal of Epidemiology
Auteur(s)
Wemakor A., Casson K., Garne E., Bakker M., Addor M.C., Arriola L., Gatt M., Khoshnood B., Klungsoyr K., Nelen V., O'Mahoney M., Pierini A., Rissmann A., Tucker D., Boyle B., de Jong-van den Berg L., Dolk H.
ISSN
1573-7284 (Electronic)
ISSN-L
0393-2990
Statut éditorial
Publié
Date de publication
2015
Volume
30
Numéro
11
Pages
1187-1198
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Evidence of an association between early pregnancy exposure to selective serotonin reuptake inhibitors (SSRI) and congenital heart defects (CHD) has contributed to recommendations to weigh benefits and risks carefully. The objective of this study was to determine the specificity of association between first trimester exposure to SSRIs and specific CHD and other congenital anomalies (CA) associated with SSRI exposure in the literature (signals). A population-based case-malformed control study was conducted in 12 EUROCAT CA registries covering 2.1 million births 1995-2009 including livebirths, fetal deaths from 20 weeks gestation and terminations of pregnancy for fetal anomaly. Babies/fetuses with specific CHD (n = 12,876) and non-CHD signal CA (n = 13,024), were compared with malformed controls whose diagnosed CA have not been associated with SSRI in the literature (n = 17,083). SSRI exposure in first trimester pregnancy was associated with CHD overall (OR adjusted for registry 1.41, 95% CI 1.07-1.86, fluoxetine adjOR 1.43 95% CI 0.85-2.40, paroxetine adjOR 1.53, 95% CI 0.91-2.58) and with severe CHD (adjOR 1.56, 95% CI 1.02-2.39), particularly Tetralogy of Fallot (adjOR 3.16, 95% CI 1.52-6.58) and Ebstein's anomaly (adjOR 8.23, 95% CI 2.92-23.16). Significant associations with SSRI exposure were also found for ano-rectal atresia/stenosis (adjOR 2.46, 95% CI 1.06-5.68), gastroschisis (adjOR 2.42, 95% CI 1.10-5.29), renal dysplasia (adjOR 3.01, 95% CI 1.61-5.61), and clubfoot (adjOR 2.41, 95% CI 1.59-3.65). These data support a teratogenic effect of SSRIs specific to certain anomalies, but cannot exclude confounding by indication or associated factors.
Mots-clé
Abnormalities, Drug-Induced/epidemiology, Adolescent, Adult, Case-Control Studies, Depression/complications, Depression/drug therapy, Europe/epidemiology, Female, Gestational Age, Heart Defects, Congenital/chemically induced, Heart Defects, Congenital/epidemiology, Heart Septal Defects, Ventricular/chemically induced, Humans, Middle Aged, Population Surveillance, Pregnancy, Pregnancy Complications/chemically induced, Pregnancy Complications/epidemiology, Pregnancy Trimester, First, Prenatal Exposure Delayed Effects/epidemiology, Registries, Risk Assessment, Risk Factors, Serotonin Uptake Inhibitors/adverse effects, Serotonin Uptake Inhibitors/therapeutic use, Socioeconomic Factors, Young Adult
Pubmed
Web of science
Création de la notice
26/01/2016 10:09
Dernière modification de la notice
03/03/2018 16:46
Données d'usage